Jefferies remained unchanged on its Danaher DHR Buy rating and $54 price target in a research report published today.
In the report, Jefferies states, "DHR's dramatic portfolio evolution has escalated its secular organic revenue growth and ROIC profiles while reducing the enterprise's operational volatility. Its considerable exposure to favorable dynamics underway in Life Sciences, Diagnostics and Dental markets is a key investment merit, in our view."
Shares of Danaher were at $46.63 in after hours trading at the time of posting, down 0.04% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in